Implantable Insulin Pump Market Report 2026

Implantable Insulin Pump Market Overview

• Implantable Insulin Pump market size has reached to $3.88 billion in 2025 • Expected to grow to $6.09 billion in 2030 at a compound annual growth rate (CAGR) of 9.3% • Growth Driver: Rising Diabetes Rates Fuel Expansion of Implantable Insulin Pump Market • Market Trend: Development Of Thermostable Insulin For Next-Generation Implantable Pumps • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Implantable Insulin Pump Market?

An implantable insulin pump is a surgically implanted device that delivers insulin directly into the peritoneal cavity, continuously releasing and adjusting doses based on the patient's needs. It helps individuals with diabetes maintain stable blood sugar levels, reducing the risk of long-term complications. This provides more effective diabetes management compared to daily injections. The main types of implantable insulin pumps are closed-loop insulin pumps and open-loop insulin pumps. Closed-loop insulin pumps, also known as artificial pancreas systems, are advanced medical devices that automatically regulate blood sugar levels in people with diabetes. It is used for several applications, such as type 1 diabetes and type 2 diabetes, by various end-users, including hospitals and home care.

What Is The Implantable Insulin Pump Market Growth Forecast?

The implantable insulin pump market size is expected to see strong growth in the next few years. It will grow to $6.09 billion in 2030 at a compound annual growth rate (CAGR) of 9.3%. The growth in the forecast period can be attributed to rising adoption of automated insulin delivery systems, advancements in implantable medical device design, increasing demand for personalized diabetes care, expansion of home-based diabetes management, favorable reimbursement and regulatory support. Major trends in the forecast period include rising adoption of implantable insulin delivery systems, growing preference for closed-loop insulin pumps, improved glycemic control through continuous insulin infusion, increasing acceptance of long-term implantable diabetes devices, enhanced focus on patient convenience and therapy adherence.

Global Implantable Insulin Pump Market Segmentation

1) By Type: Fully Implantable Insulin Pump, Semi-Implantable Insulin Pump 2) By Application: Type 1 Diabetes, Type 2 Diabetes 3) By End-User: Hospitals, Diabetes Clinics, Home-Care Subsegments: 1) By Fully Implantable Insulin Pump: Fully Automated Implantable Insulin Pump, Implantable Insulin Pump with Continuous Glucose Monitoring (CGM), Implantable Insulin Pump with Adaptive Insulin Delivery 2) By Semi-Implantable Insulin Pump: Semi-Automated Semi-Implantable Insulin Pump, Basal-Bolus Semi-Implantable Insulin Pump, Patch-Assisted Semi-Implantable Insulin Pump, Remote-Controlled Semi-Implantable Insulin Pump

What Is The Driver Of The Implantable Insulin Pump Market?

The rise in the incidences of diabetes is expected to propel the growth of the implantable insulin pump market going forward. Diabetes is a long-term condition where the body struggles to control blood sugar levels due to either inadequate insulin production or ineffective use of insulin by cells. The rise in diabetes cases is driven by factors such as higher obesity rates, lack of physical activity, unhealthy diets, and an older population. An implantable insulin pump offers precise, continuous insulin delivery, stabilizing blood glucose levels, reducing injection frequency, and improving overall diabetes management and quality of life. For instance, in May 2024, according to the Diabetes UK, a UK-based charity for diabetes people, with over 5.6 million people in the UK living with diabetes, the 2022–23 figures represent an increase of 167,822 cases compared to the previous year. Therefore, the rise in the incidences of diabetes is driving the growth of the implantable insulin pump industry.

Key Players In The Global Implantable Insulin Pump Market

Major companies operating in the implantable insulin pump market are Sanofi S.A., Abbott Laboratories, Medtronic plc, Dexcom Inc., Insulet Corporation, Tandem Diabetes Care Inc., Ypsomed Holding AG, Air Liquide Healthcare Ltd., Diabeloop SA, Glooko Inc., ViCentra B.V., Bigfoot Biomedical Inc., Beta Bionics Inc., Senseonics Holdings Inc., INREDA DIABETIC B.V., TIDEPOOL Inc., Medtrum Technologies Inc., Sernova Corp., PhysioLogic Devices Inc., EOFLOW CO. LTD., CamDiab Ltd.

Global Implantable Insulin Pump Market Trends and Insights

Major companies in the implantable insulin pump market are increasingly forming strategic partnerships to develop high-concentration, thermostable insulin formulations tailored for next-generation implantable pumps. For example, in May 2024, Arecor Therapeutics plc, a US-based biopharmaceutical company, partnered with Medtronic Diabetes, a US-based medical technology company, to create a novel insulin using Arecor’s Arestat technology platform. This advanced formulation is designed for a small group of patients who have limited options with standard insulin delivery methods. The new insulin aims to enhance clinical outcomes by enabling direct hepatic absorption, reducing pump maintenance needs, expanding physician use, and potentially lowering healthcare costs. This collaboration highlights meaningful progress in diabetes care by uniting innovative drug formulation with advanced implantable delivery technology to better support patients requiring intensive insulin management.

What Are Latest Mergers And Acquisitions In The Implantable Insulin Pump Market?

In June 2024, Arecor Therapeutics plc, a UK-based biotechnology company, partnered with Medtronic plc. to develop a high-concentration, thermostable insulin for Medtronic's advanced implantable insulin pumps. The collaboration aims to enhance treatment for diabetes patients requiring intensive insulin management. Medtronic plc is an Ireland-based manufacturer of implantable insulin pumps.

Regional Outlook

North America was the largest region in the implantable insulin pump market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain

What Defines the Implantable Insulin Pump Market?

The implantable insulin pump market consists of sales of pump devices, delivery catheters, control systems, and insulin reservoirs. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.